112 related articles for article (PubMed ID: 38788177)
1. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
2. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
Wu Y; Hu L; Zhang S; Zhang H
Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
[No Abstract] [Full Text] [Related]
3. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
7. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
9. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B
Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413
[TBL] [Abstract][Full Text] [Related]
10. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.
Shi Y; Ma X; He D; Dong B; Qiao T
Front Immunol; 2023; 14():1213222. PubMed ID: 37600799
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
13. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
14. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Conroy MR; Dennehy C; Forde PM
Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Lochrin SE; Forde PM
Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
[TBL] [Abstract][Full Text] [Related]
18. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
[TBL] [Abstract][Full Text] [Related]
19. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
Sim JK; Choi J; Lee SY
Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
[TBL] [Abstract][Full Text] [Related]
20. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G; Remon J; Hendriks LEL; García-Campelo R; Rolfo C; Van Schil P; Forde PM; Besse B; Subbiah V; Reck M; Soria JC; Peters S
Nat Rev Clin Oncol; 2023 Oct; 20(10):664-677. PubMed ID: 37488229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
